Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antiviral combination therapies for persistent COVID-19 in immunocompromised patients
Daniele Focosi, Fabrizio Maggi, Alessandra D’Abramo, et al.
International Journal of Infectious Diseases (2023) Vol. 137, pp. 55-59
Open Access | Times Cited: 16

Showing 16 citing articles:

COVID-19 therapeutics
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 8
Refractory pneumonia due to persistent SARS-CoV-2 infection in an immunocompromised host successfully treated with extended course nirmatrelvir/ritonavir
Shiro Sonoda, Sho Shimada, Atsushi Sawada, et al.
Deleted Journal (2025)
Open Access
Emerging anti-spike monoclonal antibodies against SARS-CoV-2
Eloy E. Ordaya, Raymund R. Razonable
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 3, pp. 191-201
Closed Access | Times Cited: 4
Passive immunotherapies for the next influenza pandemic
Daniele Focosi, Massimo Franchini, Jonathon W. Senefeld, et al.
Reviews in Medical Virology (2024) Vol. 34, Iss. 3
Closed Access | Times Cited: 3
Multiple antimicrobial and immune-modulating activities of cysteamine in infectious diseases
Tonino Alonzi, Alessandra Aiello, Michela Sali, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 178, pp. 117153-117153
Open Access | Times Cited: 3
Treatment of chronic COVID‐19 with convalescent/postvaccination plasma in patients with hematologic malignancies
Maike Janssen, Albrecht Leo, Cornelia Wolf, et al.
International Journal of Cancer (2024) Vol. 155, Iss. 4, pp. 618-626
Open Access | Times Cited: 2
Does early combination vs. Monotherapy improve clinical outcomes of clinically extremely vulnerable patients with COVID-19? Results from a retrospective propensity-weighted analysis
Maria Mazzitelli, Alberto Enrico Maraolo, Claudia Cozzolino, et al.
European journal of medical research (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 2
Considerations for the development of monoclonal antibodies to address new viral variants in COVID-19
Arturo Casadevall, Scott A. McConnell, Daniele Focosi
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 8, pp. 787-797
Closed Access | Times Cited: 1
The winding road: Infectious disease considerations for CAR-T and other novel adoptive cellular therapies in the era of COVID-19
Kanal Singh, Joseph M. Rocco, Véronique Nussenblatt
Seminars in Hematology (2024) Vol. 61, Iss. 5, pp. 321-332
Closed Access | Times Cited: 1
Antiviral combination treatment strategies for SARS-CoV-2 infection in immunocompromised patients
Chiara Sepulcri, Claudia Bartalucci, Małgorzata Mikulska
Current Opinion in Infectious Diseases (2024) Vol. 37, Iss. 6, pp. 506-517
Closed Access | Times Cited: 1
Early combination of sotrovimab with nirmatrelvir/ritonavir or remdesivir is associated with low rate of persisting SARS CoV-2 infection in immunocompromised outpatients with mild-to-moderate COVID-19: a prospective single center study.
Ivan Gentile, Giulio Viceconte, F. M. Cuccurullo, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Outcomes of Antiviral Retreatment for Immunocompromised Hosts With Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Polymerase Chain Reaction Positivity: A Multicenter Australian Retrospective Case Series
Katherine Bond, Claire Dendle, S Guy, et al.
Open Forum Infectious Diseases (2024) Vol. 11, Iss. 8
Open Access
The triple combination of Remdesivir (GS-441524), Molnupiravir and Ribavirin is highly efficient in inhibiting coronavirus replication in human nasal airway epithelial cell cultures and in a hamster infection model.
Thuc Nguyen Dan, Rana Abdelnabi, Bernadett Boda, et al.
Antiviral Research (2024) Vol. 231, pp. 105994-105994
Open Access
Opportunistic Infection in Hematological Malignancies
Shakti Bedanta Mishra
(2024), pp. 343-360
Closed Access
Early combination of sotrovimab with nirmatrelvir/ritonavir or remdesivir is associated with low rate of persisting SARS CoV-2 infection in immunocompromised outpatients with mild-to-moderate COVID-19: a prospective single-centre study
Ivan Gentile, Giulio Viceconte, F. M. Cuccurullo, et al.
Annals of Medicine (2024) Vol. 57, Iss. 1
Open Access
Carbonized aerogel/ZnO-based dispersive solid phase extraction of daclatasvir and sofosbuvir from biological samples prior to liquid chromatography–tandem mass spectrometry
Elnaz Marzi Khosrowshahi, Roghayeh Hassanpour Sabet, Mohammad Reza Afshar Mogaddam, et al.
Journal of Pharmaceutical and Biomedical Analysis (2023) Vol. 238, pp. 115841-115841
Closed Access | Times Cited: 1
The Role of Convalescent Plasma in COVID-19: A Conclusive Post-Pandemic Review
Massimo Franchini, Daniele Focosi
Life (2023) Vol. 13, Iss. 12, pp. 2322-2322
Open Access | Times Cited: 1
Page 1

Scroll to top